Streetbeat News

ALX

Alexander's, Inc.

Industry

REIT - Retail

Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Open

190.80

Mkt cap

981M

Volume

8.2K

High

192.40

P/E Ratio

20.77

52-wk high

251.63

Low

189.40

Div yield

0.09

52-wk low

184.76

Alexander's, a REIT, has seen a decline in its stock price due to rising US 10-year Treasury yields. The company reported a decrease in FFO for Q3 2024 compared to the previous year. Despite a strong cash position, upcoming 2025 debt maturities present a challenge.

Portfolio Pulse from

January 26, 2025 | 3:30 am

ALX Oncology Holdings, Inc. announced the grant of an inducement stock option to its new CFO, Harish Shantharam, for 600,000 shares as part of his employment agreement, in accordance with Nasdaq rules.

Portfolio Pulse from

January 22, 2025 | 9:15 pm

Alexander's, Inc. will release its fourth quarter and full year earnings on February 10, 2025, before the NYSE opens.

Portfolio Pulse from

January 22, 2025 | 6:00 pm

ALX Oncology Holdings Inc. will host a virtual event to discuss updated data from their ASPEN-06 Phase 2 trial on January 23, 2025. The trial evaluates the CD47-blocker evorpacept in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.

Portfolio Pulse from

January 21, 2025 | 10:15 pm

ALX Oncology Holdings Inc. will present updated results from its Phase 2 ASPEN-06 clinical trial of Evorpacept for HER2-positive gastric cancer at the 2025 ASCO Gastrointestinal Cancers Symposium.

Portfolio Pulse from

December 18, 2024 | 1:15 pm

ALX Resources Corp. has received shareholder approval for its acquisition by Greenridge Exploration Inc. through a court-approved plan of arrangement.

Portfolio Pulse from

December 02, 2024 | 9:30 pm

ALX Oncology has appointed Dr. Alan Sandler as its new Chief Medical Officer. Dr. Sandler brings over 30 years of experience in oncology and drug development, which could enhance ALX's strategic direction and drug development efforts.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

ALX Oncology Holdings Inc. reported its financial results for the third quarter of 2024, highlighting its ongoing efforts in developing cancer therapies that enhance the immune system.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

ALX Resources Corp. has announced the filing and mailing of its management information circular for the upcoming Annual and Special Meeting of Shareholders. The meeting will address the proposed acquisition of ALX by Greenridge Exploration Inc.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Piper Sandler analyst Alexander Goldfarb maintains an Underweight rating on Alexander's (NYSE:ALX) and lowers the price target from $135 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.